Breakthrough T1D is a leading global non-profit organization dedicated to type 1 diabetes (T1D) research and advocacy. Founded in 1970, the organization works relentlessly to improve the daily lives of people affected by T1D and to find a cure for the condition. By fostering global collaboration, investing in promising research, and influencing policies, Breakthrough T1D aims to deliver life-changing treatments and make T1D a condition of the past.
1970
23-1907729
$446.2 million
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.

Breakthrough T1D offers a comprehensive T1D Resource Library packed with information to help newly diagnosed individuals, children, teens, and adults manage type 1 diabetes and navigate their daily lives.

Breakthrough T1D provides specialized support services tailored to the needs of children, teens, and adults living with type 1 diabetes. These include guidance on clinical trials, supportive team advice, and resources such as the 'Bag of Hope' and 'Teen Pack'.

Breakthrough T1D's Centers of Excellence focus on groundbreaking research to improve treatments and work towards curing type 1 diabetes. These centers connect leading scientists and facilitate the development of innovative therapies.
Funding Millions in Global Research
Breakthrough T1D has driven millions of dollars in global investment into therapy development and access initiatives aimed at improving the lives of those living with type 1 diabetes.
Launch of T1D Fund
The T1D Fund is an innovative venture philanthropy initiative that drives critical funding towards research and development of cures for type 1 diabetes.
06/06/2024
Our Advocates traveled to D.C. to reintroduce our organization and champion legislation and policy for the T1D community.
06/10/2024
Breakthrough T1D researchers gathered at the ADA conference and presented new study results and clinical trials for T1D.
06/20/2024
Breakthrough T1D Chief Strategy Officer, Sydney Yovic, transitions to her new role as CEO of the Australia affiliate.
Overall Score
73
44
/100
Program Expense Ratio
77.26%
10
/20
Program Revenue Growth
-4.31%
2
/20
Leverage Ratio
0.3115
12
/20
Working Capital Ratio
1.424
12
/20
Fundraising Efficiency
3.153
8
/20
Fiscal Year:2022
Source:Source: Self-reported by organization
| Category | Amount | Percentage |
|---|---|---|
| Contributions, Gifts, and Grants | 190.1M | 84.94% |
| Program Services | 19.62M | 8.77% |
| Investment Income | 7.849M | 3.51% |
| Sales of Non-Inventory Assets | 1.384M | 0.62% |
| Other Notable Sources | 3.849M | 1.72% |
| Total Revenue | 223.8M | 100.00% |
Health Associations
Named Disease SupportHealth Associations
Named Disease SupportHealth Associations
Named Disease SupportHealth Associations
Named Disease SupportHealth Associations
Named Disease Support